Hua Medicine (Shanghai) Ltd. (HKG:2552) Investors Are Less Pessimistic Than Expected

When close to half the companies in the Pharmaceuticals industry in Hong Kong have price-to-sales ratios (or “P/S”) below 1.5x, you may consider Hua Medicine (Shanghai) Ltd. (HKG:2552) as a stock to avoid entirely with its 8.9x P/S ratio. However, the P/S might be quite high for a reason and it requires further investigation to determine if it’s justified.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

View our latest analysis for Hua Medicine (Shanghai)

How Has Hua Medicine (Shanghai) Performed Recently?

Recent times have been quite advantageous for Hua Medicine (Shanghai) as its revenue has been rising very briskly. Perhaps the market is expecting future revenue performance to outperform the wider…